Log in to save to my catalogue

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8d0058476b484f6287eb9b7721046793

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

About this item

Full title

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Publisher

London: Nature Publishing Group UK

Journal title

Blood cancer journal (New York), 2021-08, Vol.11 (8), p.142-142, Article 142

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865,
p
 < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cu...

Alternative Titles

Full title

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8d0058476b484f6287eb9b7721046793

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8d0058476b484f6287eb9b7721046793

Other Identifiers

ISSN

2044-5385

E-ISSN

2044-5385

DOI

10.1038/s41408-021-00534-z

How to access this item